Genetic Technologies (Genetic Technologies) 3-Year Book Growth Rate : -19.50% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies 3-Year Book Growth Rate?

Genetic Technologies's Book Value per Share for the quarter that ended in Dec. 2023 was $0.84.

During the past 12 months, Genetic Technologies's average Book Value per Share Growth Rate was -64.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -19.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was 1.70% per year. During the past 10 years, the average Book Value per Share Growth Rate was -18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Genetic Technologies was 47.00% per year. The lowest was -55.80% per year. And the median was -7.80% per year.

Competitive Comparison of Genetic Technologies's 3-Year Book Growth Rate

For the Diagnostics & Research subindustry, Genetic Technologies's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's 3-Year Book Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's 3-Year Book Growth Rate falls into.

Genetic Technologies 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Genetic Technologies (NAS:GENE) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Genetic Technologies 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.